Human Respiratory Viruses: Mechanisms, Epidemiology, Morbidity, and Contemporary Challenges to Global Health

Vaibhav Gavane[1]

[1]Department of Pharmacology, PES Modern College of Pharmacy, Nigdi- 411044, Pune, Maharashtra, India

Corresponding author: vgavane823@gmail.com
Doi: https://doi.org/10.5281/zenodo.17935404
Received: 07 December 2025
Accepted: 19 December 2025

Abstract

Among the most prevalent infectious pathogens in the globe, respiratory viruses generate an enormous number of chronic as well as acute illnesses. Multiple viruses may spread through the airways and cause illnesses that include deadly pneumonia and nasal collapse, to a small infection of the upper respiratory tract. These viruses include coronaviruses, rhinoviruses and adenoviruses, influenza-like viruses, and the syncytial virus of the respiratory tract (RSV).

These viruses utilise strategies for entering host cells, spreading, and resisting the immune system, causing an assortment of clinical manifestations and results. The pathogenesis and infection processes of important human respiratory viruses are summarised in this article, together with their epidemiological traits and range of related diseases. The causes of illness and transmission mechanisms underlying important human viral respiratory infections have been outlined in the current piece, in conjunction with the epidemiological patterns and many associated ailments. It emphasises issues such as shifts in the environment and climate, difficulties with vaccinations, the misuse of medicines and antivirals, viral mutation, outbreaks and repetition of illnesses, and healthcare disparities. The study ends by highlighting the relevance of better monitoring, inoculation efforts, infection prevention approaches, and research into emerging treatments in order to decrease the influence of viruses that cause breathing problems on global health.

Keywords: Global health, Influenza, Coronavirus, Respiratory viruses, Epidemiology, and Morbidity.

1. Introduction

A broad group of illnesses referred to as human respiratory viruses primarily infect both the upper as well as lower respiratory airways. Since they are primarily spread by droplets from the breath, aerosols, and contact with contaminated surfaces, they are especially effective at spreading inside homes, cities, and healthcare facilities [1]. Notable people's respiratory viruses encompass influenza A and B viruses, respiratory syncytial virus, also known as (RSV), respiratory adenoviruses and human influenza-like respiratory viruses (HPIVs), the human metapneumovirus. (hMPV), and different coronaviruses.

Those viruses are an important cause of respiratory tract infections (ARIs), and they are among the world's leading causes of morbidity and death, especially in countries with poor or intermediate incomes [2]. They have a significant impact on hospital stays, outpatient visits, job and school absences, and medical costs. Further demonstrating how respiratory viruses may seriously damage economies, societies, and health systems is the coronavirus disease 2019 (COVID-19) pandemic [3]. In addition to summarising the pathophysiology and infection processes of common human respiratory viruses, this review paper will describe their epidemiological patterns, look at related morbidity, and address current global health issues. It emphasises how public health viewpoints and virology concepts may be used to inform management and preventative methods.

2. Principal Respiratory Viruses in Humans

All virus families cause serious respiratory illnesses in humans. Despite variances in morphology, genome categorisation, and replication strategies, they have a similar affinity for the lung epithelium.

2.1. Influenza Viruses

The limited, negative-sense RNA with a single strand of influenza A and B viruses are part of the Orthomyxoviridae family of viruses. These differentiate by two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), which determine antigenic characteristics and subtype classification (e.g., H1N1, H3N2) [4]. Influenza viruses create seasonal epidemics and periodic pandemics, which significantly raise mortality, especially in elderly individuals and those deemed more vulnerable.

2.2. The respiratory syncytial virus, or RSV

A number of the main causes of bronchial asthma and pneumonia in infants and toddlers are the enveloped RNA virus known as respiratory syncytial virus (RSV), which falls into the respiratory viral family [5]. Furthermore, it helps cause respiratory disorders in older individuals and individuals with chronic cardiopulmonary ailments.

2.3. Human rhinoviruses

Human rhinoviruses (HRVs), enclosed in Picornaviridae, negative-sense RNA viruses that are members of the family, are the primary root cause of the "common cold" [6]. Even though asthma and chronic obstructive pulmonary disease (COPD) generally coincide with chronic infections of the upper airways, HRVs can trigger noticeable exacerbations in those with these diseases.

2.4 Coronaviruses

Human coronaviruses consist of the harmless, but slightly sick ones, such as HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, as well as those deadly, namely MERS-CoV, SARS-CoV and SARS-CoV-2 [7]. SARS-CoV-2 or the coronavirus resulted in a global pandemic, during which many people became ill, and numerous deaths were observed [3,7].

2.5 Other viruses for breathing

Others that are hard to breathe in and may bring about a ton of trouble, such as a serious cold of the upper part or even a deadly disease of the lower lung, are adenoviruses, HPIVs and human metapneumovirus. These particularly hurt the individuals who have a low immune system, those who are more than 50 years old, and children [8].

3. Mechanisms of Infection and Pathogenesis

Attachment to the host cell, infection, multiplication, distribution and evasion of host immunity are common stages in the respiratory virus infection cycle. However, each virus has receptors, interact with the tissue and immune systems, which determine the severity of the illness.

3.1. Viral infection and receptor binding.

Attachment of viruses to the host cell receptors in epithelial cells is caused by viral surface proteins. RSV attaches to cells using glycoprotein (G and F) and fuses with the cell, whereas influenza HA binds to acidic residues in epithelial cells [4,5]. In order to enter, SARS-CoV-2 employs the spike (S) protein to interact with the angiotensin-converting enzyme 2 (ACE2) receptor and adhere to it [7].

3.2. Replication and damage to tissue

Viruses replicate their genomes and produce viral proteins within the cell by using the host's cellular machinery. Particle buildup and viral cytopathic effects cause damage to epithelial cells, malfunctioning cilia, and a breakdown in mucociliary clearance [6]. In severe cases of COVID-19 pneumonia and influenza, this damage increases the likelihood of additional bacterial infections and may cause extensive alveolar damage. (3, 4). This malfunction may cause extensive alveolar damage in some situations, such as severe influenza and COVID-19 pneumonia, and increase susceptibility to further bacterial infections [3, 7].

Immunity, made up of blocking antibodies and virus-specific T cells, is necessary for persistent protection. However, several viruses have created methods to avoid or suppress the host's responses, allowing repeated sickness or protracted infection. Since influenza viruses are able to bypass established safety through drift and shift, seasonal vaccine modifications are necessary [4].

3.4. Viral complications

Respiratory viruses can cause problems that are not related to the respiratory tract. Influenza and SARS-CoV-2 have been linked to cardiovascular problems such as myocarditis, arrhythmias, and acute coronary syndromes [10]. Neurological symptoms such as encephalopathy, stroke, and Guillain-Barré syndrome have been linked to several viruses [3,10]. The rates of disease and death are significantly increased by these systemic effects.

4. Human Pulmonary Virus Epidemiology

4.1. Regional and global patterns

Although respiratory viruses are found all across the world, each virus and region has a different prevalence and seasonality. Influenza and RSV typically peak in the winter in temperate areas, although circulation may be more year-round or associated with rainy seasons in tropical regions [2,5]. Rhinoviruses often have many peaks throughout the year, particularly during seasonal shifts [6]. During the COVID-19 pandemic, public health measures temporarily stopped the transmission of some viruses, but after restrictions were put in place, the virus's circulation increased again [3].

4.2. Modes of transmission

Droplets from talking, sneezing, or coughing, as well as aerosols in some environments, particularly poorly ventilated indoor spaces, are the main routes of transmission [1,11].

In addition, propagation via contamination of surfaces or fomites is essential, particularly for viruses as adenoviruses, that remain enduring in the environment. Transmission can occur in households, workplaces, educational institutions, and medical facilities due to nearby crowding and inadequate sanitation practices [1,11].

4.3. Vulnerable groups and risks

Pulmonary viral infections are more probably result in severe disease or consequences in some groups. These include:

- Young children and newborns, especially for parainfluenza and RSV [5,8]. The aged, particularly those with coexisting diseases such as diabetes, COPD, and cardiovascular disease [2, 4].
- Pregnant women are more likely to get severe influenza [4].
- Pregnant women have an increased likelihood of serious influenza [4]. People with weakened immune systems, such as transplant recipients, bloodstream cancer patients, and those taking medicines that suppress the immune system [8].
- People residing in densely inhabited or resource-constrained locations with limited access to healthcare, immune treatment, and preventative care [2, 3].

- Conditions of poverty, poor nutrition, indoor air pollution, and lack of access to healthcare have every played played an aspect that influences the epidemiology of viral respiratory illness [2, 13].

5. Disease Impact and Morbidity

5.1 Hospitalising and mild respiratory disease

Respiratory viruses are the primary cause of respiratory conditions that include minor upper respiratory tract infections to serious pneumonia and acute respiratory distress syndrome.

Influenza, RSV, and SARS-CoV-2 are the leading causes of inpatient stays due to respiratory disorders, particularly among susceptible groups [3-5]. Individuals in medical facilities frequently want ventilation, ventilation that isn't invasive, or oxygen that is supplemental.

5.2. Aggravations of long-standing pulmonary illness

Viral respiratory diseases commonly lead to worsening of already existing chronic lung disorders such as COPD and asthma. The presence of rhinoviruses, influenza viruses, RSV, as well as additional viruses, may have been connected to an acute deterioration of breathing symptoms, leading to spikes in hospitalised and visits to hospitals [4, 6]. These acute episodes increase mortality, lower quality of life, and speed up the worsening of lung function.

5.3. Additional pulmonary and long-term consequences.

It is known that respiratory virus infections can have consequences that last. Following an infection, symptoms including post-viral cough, fatigue, and reduced physical capacity can persist for weeks or months. Also, research indicates a correlation between respiratory infections and subsequent cardiovascular events, which could potentially be mediated by prothrombotic states, endothelial dysfunction, and inflammation [10]. As a result, the prevalence of respiratory viruses endures despite the initial episode of attack.

5.4. Its impact on individuals and the economy

Respiratory virus infections have considerable direct and indirect costs. Direct payments entail outpatient visits, diagnostic testing, medications on prescription, and hospital stays, although indirect costs include absenteeism and parenting stress [2].

Pandemics like COVID-19 exacerbate these impacts, disrupting social life, trade, education, and travel [3]. The emotional impacts, such as sorrow, worry, and stigma, exacerbate the total strain on individuals and society.

6. Current Global Health Challenges

6.1. Emerging illnesses and the evolution of viruses

The rapid development and adaptation of RNA viruses are possible due to their mutation rates. Although antigenic shift can produce pandemic strains to which humans have minimal defence, antigenic drift in influenza viruses needs continuous modifications of vaccine strains [4]. The advent of SARS-CoV, MERS-CoV, and SARS-CoV-2 demonstrates coronaviruses' propensity to spread from animal hosts to people, resulting in epidemics [3, 7].

Ongoing evolution of viruses may alter a virus's virulence, spread, and sensitivity towards treatments and shots.

6.2. Misuse of antibiotics and viral resistance

Utilisation as well as misuse of antibiotics and antivirals can contribute to even more problems. It has been shown that strains of influenza become resistant against numerous drugs for antiviral purposes, such as inhibition of neuraminidase [4]. Considering their failure to work against viruses, prescription antibiotics are frequently used for pneumonia caused by viruses, contributing to the global problem of antimicrobial resistance [11]. The utilisation accentuates the need for better diagnosis, conservation projects, and public knowledge.

6.3. Reluctance and gaps in vaccination

One of the best ways to prevent serious viral respiratory diseases is still vaccination. Still, there are obstacles, like availability in areas having scarce resources, logistical difficulties, shifting strains of viruses, and vaccination reluctance brought on by false information, misunderstanding, and cultural factors [12]. These barriers need to be addressed when trying for full coverage and immunity among the community.

6.4. Equity in healthcare and societal obstacles

The burden of respiratory viral infections is particularly significant in low- and middle-income nations, in which overcrowded hospitals, poor nutrition, and lack of healthcare infrastructure heighten predisposition [2,3]. Correct identification and maintenance pose problems considering limited laboratory capabilities, and lack of airflow, ventilatory devices, and critical care beds restrict the ability to cope with serious medical conditions. The COVID-19 pandemic revealed and exacerbated the differences, showing how important it is to fund excellent medical infrastructure and appropriate access to medicine and interventions [3].

6.5. Environment and meteorological issues

Environmental variables that harm the epithelium of the lungs and raise the possibility of a viral infection with serious consequences are contact with smoke from cigarettes, indoor biomass fuel consumption, and air pollution [13]. Changes in the climate could impact the seasonality and geographical distribution of influenza viruses through changes in temperatures, humidity, and human activities. Population growth and incursion on wildlife habitats present the chance of zoonotic spread of unfamiliar bugs [7,13]. The COVID-19 pandemic emerged along with the escalation.

7. Prevention and Control Strategies

7.1. Vaccination and immunity suppression

Enhancing and extending vaccination programs is a requirement for decreasing the adverse impacts of viruses. Biennial vaccines for influenza should be distributed to those at risk, who include the elderly, pregnant women, healthcare workers, along those with ongoing illnesses [4].

COVID-19 vaccinations have been successful in decreasing serious illnesses and fatalities, but periodic booster strategies are required to combat decreasing immunity and infectious agent changes [3,7]. RSV preventive measures encompass monoclonal antibodies for both vulnerable newborns and, in recent years, vaccinations for older individuals and pregnant women [5].

7.2. Treatments without drugs

Non-drug interventions (NDIs) such as handwashing, mask deployment in areas with elevated risks, proper breathing habits, establishing physical distance, and better air flow prove crucial to minimising illness transmission while in emergencies or in extremely dangerous settings like healthcare organisations, as well as facilities for the elderly [1,11]. Through the COVID-19 pandemic, the combined use of NPIs has proved effective for minimising the global distribution of SARS-CoV-2, along with different viral respiratory illnesses [3].

7.3. Strengthening surveillance and diagnostics

Effective surveillance networks are crucial to detecting epidemics, monitoring circulating viruses, and offering data for vaccine formulation and public health actions. Polymerase chain reaction, or PCR, and multiplexed panels are instances of molecular testing that allow it to be practicable to quickly recognise some viruses and indicate optimum treatment for them [2, 3]. Adding genomic surveillance may assist in monitoring the advancement of viruses and the rise of entirely novel mutations [4,7].

7.4 Research and Innovations

Antiviral agents, sophisticated antibodies that supply prolonged epithelial immunity, as well as creative immuno modulatory therapeutics, aim to decrease disease progression of disease.
Patient care and sanitation measures will be boosted by studying viral and host functions, comprehending health indications, as well as probing effects over time [3,9,10].
Methodologies within the implementation field contribute to transferring the
intervention into concrete actions in various kinds of domains.

Approaches in applied science help with turning treatments into reality in a variety of different settings.

8. Conclusion

Human influenza viruses affect individuals of every age, generating an enormous and ongoing burden for illness worldwide and adding to numerous acute and ongoing health issues. The COVID-19 pandemic is an effective example of how effects spread transcend personal illness to include impacts on culture, the financial sector, and the wellness service. Recent issues that consist of disease formation, emerging illness, antimicrobial resistance, vaccination reservations, inequities in healthcare, and shifts in the environment reinforce the urgency for a broad and planned global intervention. Developing vaccination programs, upgrading inspections, advising caution on antibiotic use, and giving grants to research and stronger health systems are all critical to minimise the morbidity that comes from viruses of the respiratory tract, as well as boost the health of the world.

References

1. Leung, N. H. L. (2021). Transmissibility and transmission of respiratory viruses. *Nature Reviews Microbiology, 19*(8), 528–545. https://doi.org/10.1038/s41579-021-00535-6
2. Troeger, C., Blacker, B., Khalil, I. A., Zimsen, S. R. M., Albertson, S. B., Abate, D., … Mokdad, A. H. (2019). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Infectious Diseases, 19*(11), 1191–1210. https://doi.org/10.1016/S1473-3099(19)30310-4
3. Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. *JAMA, 324*(8), 782–793. https://doi.org/10.1001/jama.2020.12839
4. Kim, H., Webster, R. G., & Webby, R. J. (2018). Influenza virus: Dealing with a drifting and shifting pathogen. *Vaccine, 36*(45), 6591–6599. https://doi.org/10.1016/j.vaccine.2018.08.034
5. Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M, Madhi, S. A., Singleton, R. J., … Campbell, H. (2010). Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. *The Lancet, 375*(9725), 1545–1555. https://doi.org/10.1016/S0140-6736(10)60206-1
6. Gern, J. E. (2010). The ABCs of rhinoviruses, wheezing, and asthma. *Journal of Virology, 84*(15), 7418–7426. https://doi.org/10.1128/JVI.02290-09
7. Lamers, M. M., & Haagmans, B. L. (2022). SARS-CoV-2 pathogenesis. *Nature Reviews Microbiology, 20*(5), 270–284. https://doi.org/10.1038/s41579-022-00713-0

8. Henrickson, K. J. (2003). Parainfluenza viruses. *Clinical Microbiology Reviews, 16*(2), 242–264. https://doi.org/10.1128/CMR.16.2.242-264.2003
9. Thompson, M. R., Kaminski, J. J., Kurt-Jones, E. A., & Fitzgerald, K. A. (2011). Pattern recognition receptors and the innate immune response to viral infection. *Future Virology, 6*(10), 1323–1339. https://doi.org/10.2217/fvl.11.98
10. Long, B., Brady, W. J., Koyfman, A., & Gottlieb, M. (2020). Cardiovascular complications in COVID-19. *The American Journal of Emergency Medicine, 38*(7), 1504–1507. https://doi.org/10.1016/j.ajem.2020.04.048
11. Wang, C. C., Prather, K. A., Sznitman, J., Jimenez, J. L., Lakdawala, S. S., Tufekci, Z., & Marr, L. C. (2021). Airborne transmission of respiratory viruses. *Science, 373*(6558), eabd9149. https://doi.org/10.1126/science.abd9149
12. World Health Organisation. (2019). *Ten threats to global health in 2019*. World Health Organisation. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
13. Ciencewicki, J., & Jaspers, I. (2007). Air pollution and respiratory viral infection. *Inhalation Toxicology, 19*(14), 1135–1146. https://doi.org/10.1080/08958370701665434